Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Osimertinib in Indian Patients with EGFR T790M+ NSCLC
NCT03853551Phase 4Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2019
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Primary endpoint: Safety of Osimertinib at 5 months. Started Apr 2019; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03853551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03853551.